Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.

ABSTRACT:

Background

Although eribulin is used to treat soft tissue sarcomas (STSs), treatment data for rare subtypes are limited. We conducted a post-marketing surveillance study to assess safety and efficacy of eribulin in STS patients stratified by subtype.

Methods

Japanese patients (n = 256) with advanced or metastatic STS receiving eribulin treatment were monitored for treatment status, adverse events, diagnostic imaging, and clinical outcomes at 3 months and 1 year. Interim analysis was performed. Patients will be monitored up to 2 years.

Results

Interim analysis included 3-month (n = 255), imaging (n = 226), and 1-year (n = 105) data. STS subtype distribution was normal. Median number of eribulin cycles was 3.0 (range: 1-17 cycles). Among patients with imaging data, best

SUBMITTER: Kobayashi E 

PROVIDER: S-EPMC6886464 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature